Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
NCT02788773Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Dec 2016
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in prostate cancer (PCa), sponsored by Canadian Cancer Trials Group. Started Dec 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02788773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788773.